Bluejay Diagnostics (BJDX) announced that it has successfully enrolled 545 patients in its SYMON II multicenter clinical study and has made substantial progress in advancing manufacturing readiness and technology transfer initiatives into 2026, representing a key execution milestone as the company transitions from clinical enrollment toward data analysis, regulatory engagement, and commercialization readiness.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BJDX:
- Bluejay Diagnostics Completes 1-for-4 Reverse Stock Split
- Bluejay Diagnostics Inc trading halted, news pending
- Bluejay Diagnostics announces 1-for-4 reverse stock split
- Bluejay Diagnostics Scales IL-6 Antibody Production Capacity
- Bluejay Diagnostics completes commercial-scale IL-6 antibody production